Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis

References

• Weiner AB, Matulewicz RS, Eggener SE, et al. Increasing incidence of metastatic prostate cancer in the United States (2004-2013). Prostate Cancer Prostatic Dis. 2016;19:395–397.
   PubMed Web of Science ®Google Scholar
• Gravis G, Fizazi K, Joly F, et al. Androgen- deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:149–158.
   PubMed Web of Science ®Google Scholar
• Mukherji D, Omlin A, Pezaro C, et al. Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics. Cancer Metastasis Rev. 2014;33:555e66.
   Web of Science ®Google Scholar
• Roviello G, Sigala S, Sandhu S, et al. Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: a literature based meta-analysis of randomized trials. Eur J Cancer. 2016;61:111–121.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Vida A, Galazi M, Rudman S, et al. Enzalutamide for the treatment of metastatic castration-resistant prostate cancer. Drug Des Devel Ther. 2015;9:3325–3339.
   PubMed Web of Science ®Google Scholar
• Crawford ED, Shore ND, Petrylak DP, et al. Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility. Ther Adv Med Oncol. 2017;9:319–333.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. Bmj. 2009;339:b2535.
   PubMed Web of Science ®Google Scholar
• Zhu J, Wu J, Li G, et al. Meta-analysis of randomized controlled trials for the incidence and risk of fatal adverse events in cancer patients treated with ipilimumab. Expert Opin Drug Saf. 2017;16:423–428.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S,Cochrane Collaboration. Cochrane handbook for systematic reviews 13. Of interventions. Chichester, England; Hoboken, NJ: Wiley-Blackwell. 2008.
   Google Scholar
• De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352–360.
   PubMed Web of Science ®Google Scholar
• James ND, De Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338–351.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, De Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–148.
   PubMed Web of Science ®Google Scholar
• Sun Y, Zou Q, Sun Z, et al. Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: a randomized, double-blind, placebo-controlled phase 3 bridging study. Int J Urol. 2016;23:404–411.
   PubMed Web of Science ®Google Scholar
• Attard G, Borre M, Gurney H, et al. A phase IV, randomized, double-blind, placebo (PBO)-controlled study of continued enzalutamide (ENZA) post prostate-specific antigen (PSA) progression in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2017;35(suppl; abstr 5004).
   PubMedGoogle Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–433.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–1197.
   PubMed Web of Science ®Google Scholar
• Chowdhury S, Villers A, Shore ND, et al.Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol. 2016;17:153–163.
   PubMed Web of Science ®Google Scholar
• Penson DF, Armstrong AJ, Concepcion R, et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE Trial. J Clin Oncol. 2016;34:2098–2106.
   PubMed Web of Science ®Google Scholar
• Roviello G, Sigala S, Danesi R, et al. Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: a meta-analysis of published trials. Crit Rev Oncol Hematol. 2016;101:12–20.
   PubMed Web of Science ®Google Scholar
• Slovin SF, Clark W, Carles J, et al. Seizure rates in enzalutamide (ENZ)-treated men with metastatic castration-resistant prostate cancer (mCRPC) at increased risk of seizure: UPWARD study. Presented at ASCO-GU 2017; abstract #147.
   Google Scholar
• Desax MC, Hundsberger T, Rothermundt C, et al. Restless legs syndrome—an emerging potential side effect of enzalutamide: report of 2 cases. Clin Genitourin Cancer. 2015;13(5):e385–6.
   PubMed Web of Science ®Google Scholar
• Moore DC, Moore A. Abiraterone-induced rhabdomyolysis: a case report. J Oncol Pharm Pract. 2017;23(2):148–151.
   PubMed Web of Science ®Google Scholar
• Dineen M, Hansen E, Guancial E, et al. Abiraterone-induced rhabdomyolysis resulting in acute kidney injury: a case report and review of the literature. J Oncol Pharm Pract. 2017;1–5. doi:10.1177/1078155217701294.
   PubMed Web of Science ®Google Scholar
• Lange M, Laviec H, Castel H, et al. Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: cog-Pro trial protocol. BMC Cancer. 2017;17(1):549.
   PubMedGoogle Scholar
• Chopra A, Georgieva M, Lopes G, et al. Abiraterone or enzalutamide in advanced castration-resistant prostate cancer: an indirect comparison. Prostate. 2017;77:639–646.
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–1520.
   PubMed Web of Science ®Google Scholar
• Tannock IF, De Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–1512.
   PubMed Web of Science ®Google Scholar
• De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–1154.
   PubMed Web of Science ®Google Scholar
• Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–223.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–422.
   PubMed Web of Science ®Google Scholar